Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bryostatin-1 and Paclitaxel in Advanced Esophageal Cancer
NCT00005599Phase 2
Key facts
- Status
- Completed
- Start
- Feb 2000
- Countries
- 1
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Modality
- Small Molecules
- Drugs
- bryostatin-1
- Conditions
- esophageal cancergastric cancer (GC)
01
Overview
Phase 2, open-label, single-arm trial of bryostatin-1 in esophageal cancer and gastric cancer (GC), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Objective Response Rate. Started Feb 2000; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Paclitaxel + Bryostatin 1
Sequential paclitaxel and bryostatin 1
03
Who it enrols
Adults with locally advanced or metastatic, measurable squamous cell carcinoma or adenocarcinoma of the esophagus or GE junction, with adequate organ function, no prior taxanes or bryostatin 1, and no more than 1 prior neoadjuvant/adjuvant regimen.
04
Endpoints
Primary
Objective Response Rate
Secondary
Toxicity
Overall Survival
Quality of Life
Beyond the preview
Go deeper on NCT00005599.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005599.